Stock Information
symbol line chart

CALCCalciMedica Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Frédéric Guerard

Location

California, USA

Exchange

Nasdaq

Website

https://calcimedica.com

Summary

CalciMedica, Inc.

Company Info

CEO

Frédéric Guerard

Location

California, USA

Exchange

Nasdaq

Website

https://calcimedica.com

Summary

CalciMedica, Inc.

AI Insights for CALC
5 min read

Quick Summary

CalciMedica Inc. is a clinical-stage biopharmaceutical company based in California and listed on Nasdaq under the symbol CALC. The company is focused on developing medicines for serious diseases with high unmet medical need, including inflammatory conditions and, according to the provided fundamental profile, diseases of the retina and optic nerve. Its work is centered on drug candidates rather than commercial product sales, so the company currently reports no operating revenue. Its main customers are not traditional consumers today, but would eventually include hospitals, specialty physicians, retina specialists, critical-care physicians, ophthalmologists, payers, and healthcare systems if its candidates are approved. The company has a small employee base of about 30 people, which is typical for a development-stage biotech that relies heavily on clinical milestones, financing, regulatory progress, and external research partners.

Strengths

•

CalciMedica’s main strength is its focus on serious diseases with high unmet medical need, where even a modestly effective therapy could have significant clinical and commercial value.

•

Auxora’s CRAC-channel mechanism gives the company a differentiated scientific angle in inflammatory and organ-injury conditions.

•

The company’s small size may allow it to focus resources on a limited number of high-priority programs.

•

Any positive insider buying, clinical progress, or safety updates would likely be viewed favorably by investors because small clinical-stage biotechnology companies are highly sensitive to confidence signals.

Key Risks

•

CalciMedica faces substantial clinical risk because its value depends on drug candidates that may fail to show sufficient efficacy or safety in larger studies.

•

The company has no revenue, so it may need to raise additional capital, and that could dilute existing shareholders.

•

Biotech market conditions can be difficult for small companies, especially when interest rates are high and investors prefer profitable or lower-risk businesses.

•

Regulatory agencies may require larger, longer, or more expensive trials than investors expect.

What to Watch

The supplied financial snapshot is labeled Year 2026 and Q3, but the research should not treat that as a verified reported quarter without confirming the latest Form 10-Q or earnings release.
Based only on the provided data, CalciMedica remained a development-stage biotechnology company with no operating revenue, a net loss of about $7.652 million, operating loss of about $4.012 million, R&D expense of about $2.102 million, and SG&A expense of about $1.910 million.
The company did not report dividends, and the data does not identify a commercial product launch, partnership, regulatory approval, financing transaction, enrollment milestone, or insider purchase specifically dated to that quarter.
The most important quarter-specific follow-up for investors is to verify the actual latest filing and look for updates on clinical progress, cash runway, trial enrollment, and any capital-raising activity.

Price Drivers

•

CALC’s stock price is likely driven primarily by clinical trial results, cash runway, financing risk, insider activity, and investor appetite for small-cap biotechnology stocks.

•

The company reported negative EPS of -0.45, net income of -$7.652 million, no revenue, and negative operating income, so traditional earnings valuation is less useful than pipeline valuation.

•

The market capitalization of about $11 million indicates that even small changes in perceived clinical probability or financing outlook can create large percentage moves in the share price.

•

Macro factors such as interest rates, risk appetite, inflation, and biotech funding conditions can pressure the stock even if company-specific developments are encouraging.

Recent News

•

Recent company-related coverage has discussed CalciMedica as a small clinical-stage biopharmaceutical company with investor interest tied to insider activity, cash runway, and clinical development progress.

•

The coverage described the company as developing therapies for life-threatening inflammatory diseases using CRAC-channel technology and highlighted Auxora’s potential in acute pancreatitis, asparaginase-associated pancreatitis, and acute kidney injury.

•

Investors should confirm all news items against primary company filings, press releases, and clinical trial updates because small-cap biotechnology stocks can move sharply on incomplete or promotional information.

Market Trends

•

The broader biotechnology market is heavily influenced by clinical data, regulatory decisions, capital availability, and investor risk appetite.

•

Small-cap biotech companies have faced pressure from inflation, high interest rates, weaker economic growth, and reduced willingness to fund speculative development-stage businesses.

•

At the same time, unmet medical need in acute inflammatory diseases, organ injury, retinal disorders, and glaucoma continues to create demand for innovative therapies.

•

Investors often reward companies that can show clear clinical benefit, manageable safety risk, and a credible path to financing or partnership.

•

For CALC, favorable biotech sentiment and positive trial updates could be powerful tailwinds, while risk-off markets and financing concerns could remain major headwinds.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on CALC

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show